Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Pharmaceuticals 2010, 3(8), 2689-2708; doi:10.3390/ph3082689
Review

Cannabinoids and Dementia: A Review of Clinical and Preclinical Data

*  and
Received: 23 June 2010; in revised form: 5 August 2010 / Accepted: 16 August 2010 / Published: 17 August 2010
(This article belongs to the Special Issue Cannabinoids)
View Full-Text   |   Download PDF [98 KB, uploaded 17 August 2010]
Abstract: The endocannabinoid system has been shown to be associated with neurodegenerative diseases and dementia. We review the preclinical and clinical data on cannabinoids and four neurodegenerative diseases: Alzheimer’s disease (AD), Huntington’s disease (HD), Parkinson’s disease (PD) and vascular dementia (VD). Numerous studies have demonstrated an involvement of the cannabinoid system in neurotransmission, neuropathology and neurobiology of dementias. In addition, several candidate compounds have demonstrated efficacy in vitro. However, some of the substances produced inconclusive results in vivo. Therefore, only few trials have aimed to replicate the effects seen in animal studies in patients. Indeed, the literature on cannabinoid administration in patients is scarce. While preclinical findings suggest causal treatment strategies involving cannabinoids, clinical trials have only assessed the suitability of cannabinoid receptor agonists, antagonists and cannabidiol for the symptomatic treatment of dementia. Further research is needed, including in vivo models of dementia and human studies.
Keywords: cannabinoids; Alzheimer’s disease; Huntington’s disease; Parkinson’s disease; vascular dementia cannabinoids; Alzheimer’s disease; Huntington’s disease; Parkinson’s disease; vascular dementia
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Walther, S.; Halpern, M. Cannabinoids and Dementia: A Review of Clinical and Preclinical Data. Pharmaceuticals 2010, 3, 2689-2708.

AMA Style

Walther S, Halpern M. Cannabinoids and Dementia: A Review of Clinical and Preclinical Data. Pharmaceuticals. 2010; 3(8):2689-2708.

Chicago/Turabian Style

Walther, Sebastian; Halpern, Michael. 2010. "Cannabinoids and Dementia: A Review of Clinical and Preclinical Data." Pharmaceuticals 3, no. 8: 2689-2708.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert